ChromaDex: Looking To Take The Big Step Into Pharma

A great deal has happened since my last ChromaDex Corporation (NASDAQ:CDXC) article, where I highlighted how the company is a leader in the development of nicotinamide adenine dinucleotide (NAD+) for healthy aging utilizing their product, Tru Niagen. I also discussed how ChromaDex was reporting strong growth, improving gross margins, and had an attractive 1.3x price-to-sales valuation. As a result, I put CDXC on my watch list for inclusion in the "Bio Boom" speculative portfolio. Unfortunately, market condi ...